Cargando…

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study

PURPOSE: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with (18)F-FDG PET/CT. METHODS: (18)F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hribernik, Nežka, Huff, Daniel T, Studen, Andrej, Zevnik, Katarina, Klaneček, Žan, Emamekhoo, Hamid, Škalic, Katja, Jeraj, Robert, Reberšek, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016045/ https://www.ncbi.nlm.nih.gov/pubmed/34958422 http://dx.doi.org/10.1007/s00259-021-05650-3

Ejemplares similares

Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience
por: Hribernik, Nezka, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
por: Valentinuzzi, Damijan, et al.
Publicado: (2020)

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
por: Skoblar Vidmar, Marija, et al.
Publicado: (2022)

Breast cancer risk assessment and risk distribution in 3,491 Slovenian women invited for screening at the age of 50; a population-based cross-sectional study
por: Jarm, Katja, et al.
Publicado: (2023)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
por: Usyk, Mykhaylo, et al.
Publicado: (2021)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
por: Hu, Weilei, et al.
Publicado: (2020)

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
por: Trinh, Beckey, et al.
Publicado: (2019)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
por: Xu, Yantao, et al.
Publicado: (2022)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
por: Fox, Douglas B., et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis in Patients with Early-stage Non-small-cell Lung Cancer after Surgical Resection
por: Nezka, Hribernik, et al.
Publicado: (2019)

Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
por: Lv, Xiaohui, et al.
Publicado: (2022)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022)

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
por: Taylor, Chelsea A., et al.
Publicado: (2022)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
por: Naidoo, Jarushka, et al.
Publicado: (2017)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
por: Griss, Johannes, et al.
Publicado: (2019)

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
por: de Azevedo, Ricardo A., et al.
Publicado: (2020)

Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma
por: Takai, Erina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83j8hckadeo3vs57nr4hkp8b9d